Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.164 EUR | +0.52% | +2.28% | -20.82% |
Mar. 13 | Transcript : Agfa-Gevaert NV, 2023 Earnings Call, Mar 13, 2024 | |
Mar. 13 | Agfa-Gevaert NV Reports Impairment Losses on Intangibles and Pp&E for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.17 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.82% | 192M | B+ | ||
+8.07% | 219B | B | ||
+6.59% | 183B | B- | ||
+11.26% | 133B | B- | ||
+26.57% | 108B | A- | ||
+13.35% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.93% | 40.37B | A | ||
+11.54% | 39.35B | - | ||
+26.76% | 32.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AGFB Stock
- Ratings Agfa-Gevaert NV